

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Nativ Segev
Date of last notice	16 February 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Director and Sole Shareholder
Date of change	17 October 2016
No. of securities held prior to change	40,000,000 Fully Paid Ordinary Shares 20,000,000 Performance Shares
Class	Performance Rights - 60% vesting on 31 December 2016 and 40% vesting on 31 December 2017
Number acquired	12,500,000
Number disposed	0

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil cash - issued following shareholder approval on 27/09/2016 Estimated Valuation: \$600,000 based on the share price of \$0.048 on the date of issue, assuming all the performance milestones are met in full.
No. of securities held after change	40,000,000 Fully Paid Ordinary Shares 20,000,000 Performance Shares Bright Global Limited 12,500,000 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights were issued following approval at the Company's shareholder meeting held on 27/09/2016. The terms and conditions are detailed in the Notice of Meeting issued 26/08/2016.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Roby Reuven Zomer
Date of last notice	16 February 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Director and Sole Shareholder
Date of change	17 October 2016
No. of securities held prior to change	20,000,000 Fully Paid Ordinary Shares 10,000,000 Performance Shares
Class	Performance Rights - 60% vesting on 31 December 2016 and 40% vesting on 31 December 2017
Number acquired	10,000,000
Number disposed	0

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil cash - issued following shareholder approval on 27/09/2016 Estimated Valuation: \$480,000 based on the share price of \$0.048 on the date of issue, assuming all the performance milestones are met in full.
No. of securities held after change	Chitta Lu Limited 20,000,000 Fully Paid Ordinary Shares 10,000,000 Performance Shares 10,000,000 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights were issued following approval at the Company's shareholder meeting held on 27/09/2016. The terms and conditions are detailed in the Notice of Meeting issued 26/08/2016.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brett Anthony Mitchell
Date of last notice	14 July 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Trustee
Date of change	17 October 2016
No. of securities held prior to change	Brett and Michelle Mitchell <Mitchell Spring Family A/C> 9,458,889 Ordinary Shares 1,500,000 Unlisted Options exercisable at \$0.025 each on or before 30 June 2017 1,500,000 Unlisted Options exercisable at \$0.04 each on or before 30 June 2017 800,000 Unlisted Options exercisable at \$0.20 each on or before 30 June 2017 Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 1,735,005 Ordinary Shares 1,000,000 Unlisted Options exercisable at \$0.025 each on or before 30 June 2017 1,000,000 Unlisted Options exercisable at \$0.04 each on or before 30 June 2017
Class	Performance Rights - 60% vesting on 31 December 2016 and 40% vesting on 31 December 2017

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	10,000,000
Number disposed	0
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil cash - issued following shareholder approval on 27/09/2016 Estimated Valuation: \$480,000 based on the share price of \$0.048 on the date of issue, assuming all the performance milestones are met in full.
No. of securities held after change	Brett and Michelle Mitchell <Mitchell Spring Family A/C> 9,458,889 Ordinary Shares 8,000,000 Performance Rights 1,500,000 Unlisted Options exercisable at \$0.025 each on or before 30 June 2017 1,500,000 Unlisted Options exercisable at \$0.04 each on or before 30 June 2017 800,000 Unlisted Options exercisable at \$0.20 each on or before 30 June 2017 Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 1,735,005 Ordinary Shares 2,000,000 Performance Rights 1,000,000 Unlisted Options exercisable at \$0.025 each on or before 30 June 2017 1,000,000 Unlisted Options exercisable at \$0.04 each on or before 30 June 2017
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights were issued following approval at the Company's shareholder meeting held on 27/09/2016. The terms and conditions are detailed in the Notice of Meeting issued 26/08/2016.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.